USPH240920P85000
- 1.00
- 0.000.00%
US Physical Therapy Newsroom
US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $108
BofA Securities Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $114
Maintaining 'Buy' Rating on US Physical Therapy Amid Cost Pressures and Revenue Growth
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating for US Physical Therapy: Strong Performance and Positive Growth Outlook
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)
US Physical Therapy Analyst Ratings
US Physical Therapy Analyst Ratings
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $120
US Physical Therapy Analyst Ratings
JP Morgan Maintains Overweight on US Physical Therapy, Lowers Price Target to $99
US Physical Therapy Analyst Ratings
US Physical Therapy Analyst Ratings
Barrington Cuts Price Target on U.S. Physical Therapy to $111 From $124 on 'Tough Stock Market Environment', Reiterates Outperform Rating
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and CareDx (CDNA)
Potential Growth and Buy Rating for US Physical Therapy Despite Lower Q4 Outlook and Adjusted Price Objective
JP Morgan Initiates Coverage On US Physical Therapy With Overweight Rating, Announces Price Target of $108
US Physical Therapy Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: US Physical Therapy (USPH), Calliditas Therapeutics (CALT)